CESTY yields 3.18% · PFE yields 6.13%● Live data
📍 CESTY pulled ahead of the other in Year 1
Combined, CESTY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CESTY + PFE for your $10,000?
Chinese Estates Group (the "Group") is one of the leading property developers in Hong Kong. Chinese Estates Holdings Limited is the holding company of the Group and it is publicly listed on The Stock Exchange of Hong Kong Limited with stock code: 127. Chinese Estates' core businesses comprise of property investment for rental and property development for sale. The Group focuses primarily in Hong Kong, and diversifies its property interests to mainland China and the United Kingdom. The Group's investment properties include retail and office assets. Most of the investment properties of Chinese Estates are highly accessible and strategically located in prime commercial areas in Hong Kong such as Causeway Bay and Wanchai. In mainland China, Chinese Estates owns a five-star international hotel in Beijing. In the United Kingdom, Chinese Estates owns four investment properties in London. Over the past twenty years, Chinese Estates has built a reputation for conceptualising and implementing redevelopment, renovation works and repackaging programmes to enhance the value and revenue of its investment properties. Chinese Estates specializes in developing mid to high-end commercial and residential property projects. A number of quality and cosmopolitan residential properties are developed for sale.
Full CESTY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.